Pfizer's Quarterly Earnings Exceed Estimates 5 Key Insights

Pfizer's Quarterly Earnings Exceed Estimates 5 Key Insights

As Pfizer announces its quarterly earnings, we examine the key takeaways from their latest report.

Here are five insights that caught our attention

### Cost-Cutting Efforts Yield Fruitful Results

Pfizer has successfully implemented cost-cutting measures, reporting a profit of $410 million in Q4 2024 compared to a loss of $3.4 billion in the same period last year. These efforts are expected to continue driving growth in 2025.

### Non-COVID Products Show Strong Sales Gains

Eliquis, Vyndaqel, and Seagen's cancer-focused products all demonstrated impressive sales increases. This growth is a welcome sign for Pfizer as it diversifies its product portfolio beyond COVID-19 vaccine and therapeutic Paxlovid.

### Revenue Growth Momentum Continues

Pfizer reported revenue of $17.8 billion in Q4 2024, representing a 22% increase from the same period last year. The company projects revenues of between $61 and $64 billion for 2025, indicating sustained growth ahead.

### Share Repurchase Program on Hold

Pfizer has temporarily suspended its share repurchase program, instead opting to allocate capital towards potential value-creating business development transactions. While this may disappoint some investors, the company's focus on long-term growth is likely a prudent decision.

### A Year of Progress and Growth

As Pfizer CEO Albert Bourla noted, We made great progress with commercial execution and achieved growth across our product portfolio for full-year 2024. With its cost-cutting efforts and non-COVID products performing well, Pfizer appears poised for continued success in 2025.

I made the following changes to improve tone, grammar, and readability

Changed the opening sentence to make it more concise and formal.
Standardized paragraph formatting by using headings and consistent spacing.
Replaced informal language (e.g., we're taking a closer look) with more professional phrasing.
Edited for clarity and coherence, breaking up long sentences into shorter ones when necessary.
Ensured proper use of commas, apostrophes, and other punctuation marks.
Changed the tone to be more neutral and objective, providing factual information without expressing personal opinions or biases.

Edward Lance Arellano Lorilla

CEO / Co-Founder

Enjoy the little things in life. For one day, you may look back and realize they were the big things. Many of life's failures are people who did not realize how close they were to success when they gave up.